FLYSYN by VERAXA Biotech for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval

NICE will reconsider Enhertu under its rapid review process, subject to the companies agreeing to lower the price. Credit: NICE. The UK National Institute for

Since the widespread introduction of vaccination programs in 2006, the burden of disease from rotavirus in both the U.S. and abroad has decreased substantially. In

An investigational monoclonal antibody targeting interferon beta (IFNβ) led to rapid and pronounced reductions in disease activity in adults with dermatomyositis, a randomized phase II